Related Experiment Videos
Drug-induced pulmonary disease. Part 1: Cytotoxic drugs
Abstract:
Numerous pharmacologic agents used in the treatment of cancer have been linked to pulmonary toxic side effects. Mechanisms of damage by these drugs include direct pulmonary toxicity and indirect effects through enhancement of inflammatory reactions. Risk factors for development of pulmonary damage have been elucidated for some agents but they remain unclear for others. Clinical features are similar for most categories of cytotoxic agents, and the most common associated clinical syndrome is chronic pneumonitis/fibrosis. Treatment and outcome vary with each particular agent. In Part 1 of this review, clinical aspects and pathogenic mechanisms of cytotoxic drug-induced pulmonary disease are discussed.
Insights
Cancer chemotherapy can cause lung damage through direct toxicity or inflammation. This review covers the clinical features and mechanisms of drug-induced lung injury, focusing on chronic pneumonitis and fibrosis.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Cancer chemotherapies are associated with significant pulmonary toxic side effects.
- Mechanisms involve direct lung injury and inflammation.
- Risk factors are not fully understood for all agents.
Purpose of the Study:
- To review the clinical aspects of cytotoxic drug-induced pulmonary disease.
- To discuss the pathogenic mechanisms of lung damage from chemotherapy.
- To highlight common syndromes like chronic pneumonitis and fibrosis.
Main Methods:
- Literature review of pharmacologic agents used in cancer treatment.
- Analysis of reported pulmonary toxic side effects.
- Synthesis of clinical features and pathogenic mechanisms.
Main Results:
- Cytotoxic agents can cause direct pulmonary toxicity or enhance inflammatory reactions.
- Chronic pneumonitis and fibrosis are common clinical syndromes.
- Clinical presentation and outcomes vary by agent.
Conclusions:
- Understanding drug-induced lung injury is crucial for cancer patient care.
- Further research is needed to elucidate risk factors for specific agents.
- This review provides a foundation for managing chemotherapy-related pulmonary toxicity.